AAPS PharmSciTech

, Volume 19, Issue 3, pp 1141–1151 | Cite as

Fabrication of Tip-Dissolving Microneedles for Transdermal Drug Delivery of Meloxicam

  • Jianmin Chen
  • Weiyue Huang
  • Ziyao Huang
  • Shiqi Liu
  • Yaling Ye
  • Qinglian Li
  • Meiping Huang
Research Article
  • 63 Downloads

Abstract

Dissolving microneedles (MNs) offered a simple, minimally invasive method for meloxicam (MX) delivery to the skin. However, the fabrication of dissolving MNs still faced some challenges, such as significant time consumption, loss of drug activity, and difficulty in regulating MN drug loading. To address these issues, we developed the tip-dissolving (TD) MNs. Several kinds of drugs were encapsulated successfully, and the quantity of MX ranged from 37.23 ± 8.40 to 332.53 ± 13.37 μg was precisely controlled. The effects of fabrication process on biomacromolecules stability were studied, and it was found that tyrosinase kept 90.4% activity during the fabrication process. The whole process for the fabrication of MNs only takes approximately 1 h. In order to further evaluate the potential of the TD MNs, MX TD MNs were prepared for in vitro release experiments, in vivo release experiments, safety evaluation, pharmacokinetic studies, and pharmacodynamic studies. The results demonstrated that MX TD MNs offered several advantages, including rapid release of the encapsulated drug (91.72% within 30 min), efficient drug delivery to skin (79.18%), no obvious skin irritation, decent relative bioavailability (122.3%), and strong anti-inflammatory and analgesic effects. Based on these results, we envisage that the TD MNs have promising potential for transdermal drug delivery of MX.

KEY WORDS

meloxicam microneedles transdermal drug delivery pharmacokinetics pharmacodynamics 

Notes

Acknowledgements

This work was supported by the Natural Science Foundation of Fujian Province (Grant No. 2015J05167), the Education Department of Fujian Province (Grant No. JZ160470), the Program for Distinguished Young Talents in Fujian Province University, Putian University (Grant Nos. 2014052 and 2015075), and Training Program of Innovation and Entrepreneurship for Undergraduates (Grant Nos. 201711498004, 201711498055, and 201711498070).

References

  1. 1.
    Degner F, Sigmund R, Zeidler H. Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin Ther. 2000;22(4):400–10.  https://doi.org/10.1016/S0149-2918(00)89009-8.CrossRefPubMedGoogle Scholar
  2. 2.
    Senna GE, Passalacqua G, Dama A, Crivellaro M, Schiappoli M, Bonadonna P, et al. Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. Eur Ann Allergy Clin Immunol. 2003;35(10):393–6.PubMedGoogle Scholar
  3. 3.
    Pairet M, van Ryn J, Schierok H, Mauz A, Trummlitz G, Engelhardt G. Differential inhibition of cyclooxygenases-1 and -2 by meloxicam and its 4′-isomer. Inflamm Res. 1998;47(6):270–6.  https://doi.org/10.1007/s000110050329.CrossRefPubMedGoogle Scholar
  4. 4.
    Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol. 1996;35(Suppl 1):68–77.  https://doi.org/10.1093/rheumatology/35.suppl_1.68.CrossRefPubMedGoogle Scholar
  5. 5.
    Lanes SF, Rodrigeuz LA, Hwangg E. Baseline risk of gastrointestinal disorders among new users of meloxicam, ibuprofen, diclofenac, naproxen and indomethacin. Pharmacoepidemiology and drug safety. 2000;9(2):113–7. doi:  https://doi.org/10.1002/(SICI)1099-1557(200003/04)9:2<113::AID-PDS478>3.0.CO;2–2.
  6. 6.
    Chen J, Gao Y. Strategies for meloxicam delivery to and across the skin: a review. Drug Delivery. 2016;23(8):3146–56.  https://doi.org/10.3109/10717544.2016.1157839.CrossRefPubMedGoogle Scholar
  7. 7.
    Altman RD, Barthel HR. Topical therapies for osteoarthritis. Drugs. 2011;71(10):1259–79.  https://doi.org/10.2165/11592550-000000000-00000.CrossRefPubMedGoogle Scholar
  8. 8.
    Wiechers JW. The barrier function of the skin in relation to percutaneous absorption of drugs. Pharmaceutisch weekblad Scientific edition. 1989;11(6):185–98.  https://doi.org/10.1007/BF01959410.CrossRefPubMedGoogle Scholar
  9. 9.
    YC A, Choi JK, Choi YK, Ki HM, Bae JHA. Novel transdermal patch incorporating meloxicam: in vitro and in vivo characterization. Int J Pharm. 2010;385(385):12–9.Google Scholar
  10. 10.
    Badran MM, Taha EI, Tayel MM, Al-Suwayeh SA. Ultra-fine self nanoemulsifying drug delivery system for transdermal delivery of meloxicam: dependency on the type of surfactants. J Mol Liq. 2014;190(190):16–22.  https://doi.org/10.1016/j.molliq.2013.10.015.CrossRefGoogle Scholar
  11. 11.
    Pathan I, Mangle M, Bairagi S. Design and characterization of nanoemulsion for transdermal delivery of meloxicam. Analytical. Chem Lett. 2016:286–95.Google Scholar
  12. 12.
    Sareen R, Kumar S, Gupta GD. Meloxicam carbopol-based gels: characterization and evaluation. Current Drug Delivery. 2011;8(4):407–15.  https://doi.org/10.2174/156720111795768013.CrossRefPubMedGoogle Scholar
  13. 13.
    Duangjit S, Obata Y, Sano H, Onuki Y, Opanasopit P, Ngawhirunpat T, et al. Comparative study of novel ultradeformable liposomes: menthosomes, transfersomes and liposomes for enhancing skin permeation of meloxicam. Biol Pharm Bull. 2014;37(2):239–47.  https://doi.org/10.1248/bpb.b13-00576.CrossRefPubMedGoogle Scholar
  14. 14.
    Fang JY, Sung KC, Wang JJ, Chu CC, Chen KT. The effects of iontophoresis and electroporation on transdermal delivery of buprenorphine from solutions and hydrogels. J Pharm Pharmacol. 2002;54(10):1329–37.  https://doi.org/10.1211/002235702760345392.CrossRefPubMedGoogle Scholar
  15. 15.
    Kim TY, Kim YI, Seo SK, Kim SH, Yang KH, Shin SC. Anti-Hyperalgesic effects of meloxicam hydrogel via phonophoresis in acute inflammation in rats; comparing systemic and topical application. Biomol Ther. 2009;17(3):305–10.  https://doi.org/10.4062/biomolther.2009.17.3.305.CrossRefGoogle Scholar
  16. 16.
    Garland MJ, Migalska K, Mahmood TMT, Singh TRR, Woolfson AD, Donnelly RF. Microneedle arrays as medical devices for enhanced transdermal drug delivery. Expert Rev Med Devices. 2011;8(4):459–82.  https://doi.org/10.1586/erd.11.20.CrossRefPubMedGoogle Scholar
  17. 17.
    Henry S, Mcallister DV, Allen MG, Prausnitz MR. Microfabricated microneedles: a novel approach to transdermal drug delivery. J Pharm Sci. 1998;87(8):922–5.  https://doi.org/10.1021/js980042+.CrossRefPubMedGoogle Scholar
  18. 18.
    Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery ☆. Adv Drug Deliv Rev. 2012;64(14):1547–68.  https://doi.org/10.1016/j.addr.2012.04.005.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Donnelly RF, Garland MJ, Morrow DIJ, Migalska K, Singh TRR, Majithiya R, et al. Optical coherence tomography is a valuable tool in the study of the effects of microneedle geometry on skin penetration characteristics and in-skin dissolution. J Control Release. 2010;147(3):333–41.  https://doi.org/10.1016/j.jconrel.2010.08.008.CrossRefPubMedGoogle Scholar
  20. 20.
    Kaushik S, Hord AH, Denson DD, Mcallister DV, Smitra S, Allen MG, et al. Lack of pain associated with microfabricated microneedles. Anesth Analg. 2001;92(2):502–4.  https://doi.org/10.1213/00000539-200102000-00041.CrossRefPubMedGoogle Scholar
  21. 21.
    Witting M, Obst K, Pietzsch M, Friess W, Hedtrich S. Feasibility study for intraepidermal delivery of proteins using a solid microneedle array. Int J Pharm. 2015;486(1–2):52–8.  https://doi.org/10.1016/j.ijpharm.2015.03.046.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen J, Qiu Y, Zhang S, Yang G, Gao Y. Controllable coating of microneedles for transdermal drug delivery. Drug Dev Ind Pharm. 2013;41(3):415–22.  https://doi.org/10.3109/03639045.2013.873447.CrossRefPubMedGoogle Scholar
  23. 23.
    Gill HS, Prausnitz MR. Coating formulations for microneedles. Pharm Res. 2007;24(7):1369–80.  https://doi.org/10.1007/s11095-007-9286-4.CrossRefPubMedGoogle Scholar
  24. 24.
    Khan H, Mehta P, Msallam H, Armitage D, Ahmad Z. Smart microneedle coatings for controlled delivery and biomedical analysis. J Drug Target. 2014;22(9):790–5.  https://doi.org/10.3109/1061186X.2014.921926.CrossRefPubMedGoogle Scholar
  25. 25.
    Chen JQY, Zhang S, Gao Y. Dissolving microneedle-based intradermal delivery of interferon-α-2b. Drug Dev Ind Pharm. 2016;42(6):890–6.  https://doi.org/10.3109/03639045.2015.1096282.CrossRefPubMedGoogle Scholar
  26. 26.
    Jun H, Han MR, Kang NG, Park JH, Park JH. Use of hollow microneedles for targeted delivery of phenylephrine to treat fecal incontinence. J Control Release. 2015;207:1–6.  https://doi.org/10.1016/j.jconrel.2015.03.031.CrossRefPubMedGoogle Scholar
  27. 27.
    Lutton REM, Larrañeta E, Kearney MC, Boyd P, Woolfson AD, Donnelly RFA. Novel scalable manufacturing process for the production of hydrogel-forming microneedle arrays. Int J Pharm. 2015;494(1):417–29.  https://doi.org/10.1016/j.ijpharm.2015.08.049.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Ahmad Z, Stride E, Edirisinghe M. Novel preparation of transdermal drug-delivery patches and functional wound healing materials. J Drug Target. 2009;17(9):724–9.  https://doi.org/10.3109/10611860903085386.CrossRefPubMedGoogle Scholar
  29. 29.
    Amodwala S, Kumar P, Thakkar HP. Statistically optimized fast dissolving microneedle transdermal patch of meloxicam: a patient friendly approach to manage arthritis. Eur J Pharm Sci. 2017;104:114–23.  https://doi.org/10.1016/j.ejps.2017.04.001.CrossRefPubMedGoogle Scholar
  30. 30.
    Larrañeta E, Stewart S, Fallows SJ, Birkhäuer LL, Mccrudden MTC, Woolfson AD, et al. A facile system to evaluate in vitro drug release from dissolving microneedle arrays. Int J Pharm. 2016;497(1):62–9.  https://doi.org/10.1016/j.ijpharm.2015.11.038.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Vijaya Kumar SG, Mishra DN. Preparation, characterization and in vitro dissolution studies of solid dispersion of meloxicam with PEG 6000. Yakugaku Zasshi. J Pharm Soc Japan. 2006;126(8):657–64.  https://doi.org/10.1248/yakushi.126.657.CrossRefGoogle Scholar
  32. 32.
    Chang J-S, P-C W, Huang Y-B, Tsai Y-H. In-vitro evaluation of meloxicam permeation using response surface methodology. J Food Drug Anal. 2006;14(3)Google Scholar
  33. 33.
    Momtaz S, Lall N, Basson A. Inhibitory activities of mushroom tyrosine and DOPA oxidation by plant extracts. S Afr J Bot. 2008;74(4):577–82.  https://doi.org/10.1016/j.sajb.2008.02.005.CrossRefGoogle Scholar
  34. 34.
    Winter CAREA, Nuss GW. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Exp Biol Med. 1962;111(3):544–7.  https://doi.org/10.3181/00379727-111-27849.CrossRefGoogle Scholar
  35. 35.
    Millan MJ. Serotonin and pain: evidence that activation of 5-HT 1A receptors does not elicit antinociception against noxious thermal, mechanical and chemical stimuli in mice. Pain. 1994;58(1):45–61.  https://doi.org/10.1016/0304-3959(94)90184-8.CrossRefPubMedGoogle Scholar
  36. 36.
    Kitchen I, Green PG. Differential effects of di-isopropylfluorophosphate poisoning and its treatment on opioid antinociception in the mouse. Life Sciences. 1983;33(Suppl 1):669–72.CrossRefPubMedGoogle Scholar
  37. 37.
    Donnelly RF, Morrow DI, Singh TR, Migalska K, Mccarron PA, O’Mahony C, et al. Processing difficulties and instability of carbohydrate microneedle arrays. Drug Dev Ind Pharm. 2009;35(10):1242–54.  https://doi.org/10.1080/03639040902882280.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Chu LY, Choi SO, Prausnitz MR. Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery: bubble and pedestal microneedle designs. J Pharm Sci. 2010;99(10):4228–38.  https://doi.org/10.1002/jps.22140.CrossRefPubMedGoogle Scholar
  39. 39.
    Hong X, Wei L, Wu F, Wu Z, Chen L, Liu Z, et al. Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine. Drug Des Dev Therap. 2013;7(3):945–52.Google Scholar
  40. 40.
    Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(16):1613.Google Scholar
  41. 41.
    Cohn D, Salomon AH. Designing biodegradable multiblock PCL/PLA thermoplastic elastomers. Biomaterials. 2005;26(15):2297–305.  https://doi.org/10.1016/j.biomaterials.2004.07.052.CrossRefPubMedGoogle Scholar
  42. 42.
    Chu LY, Prausnitz MR. Separable arrowhead microneedles. J Controll Release Off J Controll Release Society. 2011;149(3):242–9.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2017

Authors and Affiliations

  • Jianmin Chen
    • 1
    • 2
  • Weiyue Huang
    • 1
  • Ziyao Huang
    • 1
  • Shiqi Liu
    • 1
  • Yaling Ye
    • 1
  • Qinglian Li
    • 1
  • Meiping Huang
    • 1
  1. 1.School of Pharmacy and Medical TechnologyPutian UniversityFujianChina
  2. 2.Key Laboratory of Pharmaceutical Analysis and Laboratory Medicine (Putian University)Fujian Province UniversityFujianChina

Personalised recommendations